The current financial score of Entera Bio Ltd is 6.48. Its financial status is robust, and its operating efficiency is low.
The current valuation score of Entera Bio Ltd is 7.87. Its current P/E ratio is -11.30, which is -85.86% below the recent high of -1.60 and -32.43% above the recent low of -14.97.
The current earnings forecast score of Entera Bio Ltd is 8.00. The average price target is 9.00, with a high of 9.00 and a low of 9.00.
The current price momentum score of Entera Bio Ltd is 4.71. Currently, the stock price is trading between the resistance level at 3.45 and the support level at 2.57, making it suitable for range-bound swing trading.
The current institutional shareholding score of Entera Bio Ltd is 3.00. The latest institutional shareholding proportion is 17.10%, representing a quarter-over-quarter decrease of 24.51%. The largest institutional shareholder is James Simons, holding a total of 368.85K shares, representing 0.00% of shares outstanding, with 451.53% increase in holdings.
The current risk assessment score of Entera Bio Ltd is 1.67. The company's beta value is 1.54. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.